Literature DB >> 9817534

The natural history of multiple sclerosis: update 1998.

B G Weinshenker1.   

Abstract

The definition of multiple sclerosis (MS) is problematic. MS is best appreciated as a series of syndromes with unique but overlapping clinical and pathological features. Each has a distinct prognosis. Prototypic MS is a relapsing-remitting disease that culminates in a secondarily progressive course in most patients. Several clinical and demographic features permit stratification of patients according to risk of advanced permanent disability. It will be critical to determine if currently available "long-term treatments" truly have an impact on the long-term course of MS.

Entities:  

Mesh:

Year:  1998        PMID: 9817534     DOI: 10.1055/s-2008-1040881

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  23 in total

Review 1.  Multiple sclerosis and the role of immune cells.

Authors:  Rune A Høglund; Azzam A Maghazachi
Journal:  World J Exp Med       Date:  2014-08-20

Review 2.  Glial grafting for demyelinating disease.

Authors:  V Tepavcević; W F Blakemore
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

Review 3.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

Review 4.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

5.  [Pharmaceutical prescription for multiple sclerosis : evaluation of pharmaceutical consumption at private health insurance].

Authors:  F Wild
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

6.  Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.

Authors:  A Achiron; M Gurevich; Y Snir; E Segal; M Mandel
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

7.  MHC mismatch results in neural progenitor cell rejection following spinal cord transplantation in a model of viral-induced demyelination.

Authors:  Jason G Weinger; Brian M Weist; Warren C Plaisted; Suzi M Klaus; Craig M Walsh; Thomas E Lane
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

8.  Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.

Authors:  Paulus S Rommer; Olaf Stüve
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

9.  Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.

Authors:  Anat Achiron; Irena Kishner; Mark Dolev; Yael Stern; Mordechai Dulitzky; Eyal Schiff; Reuven Achiron
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 10.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.